Results 111 to 120 of about 37,814 (299)

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Real‐World 10‐Year Outcomes of Anti‐VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background This study examines the long‐term effectiveness of anti‐VEGF therapy in managing neovascular age‐related macular degeneration (nAMD). Despite the well‐established short‐term improvements of anti‐VEGF therapy, there is limited data on its continued efficacy over extended periods.
Kimberly Spooner, Geoffrey Broadhead, Samantha Fraser‐Bell, Thomas Hong, James G. Wong, Andrew A. Chang   +5 more
wiley   +1 more source

1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy [PDF]

, 2015
published_or_final_versio
Gangwani, RA, Iu, LPL, Li, Q, Li, X, Ng, LK, Shi, X, Wong, YHI, Zhao, P   +7 more
core   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2473-2484, May 2025.
Abstract Aims Anti‐vascular endothelial growth factor (VEGF) therapy is the standard treatment for diabetic macular oedema (DMO); however, unmet needs remain. This study aimed to assess the effectiveness of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in treating DMO.
Ryoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, Tomoaki Tatsumi, Sho Takahashi, Kengo Nagashima, Ko Ishikawa, Tomomi Kaiho, Noriko Asaumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote, The COMET Trial investigators   +12 more
wiley   +1 more source

Use of Ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials

Scientific Reports, 2023
Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME), but is less effective in some patients.
Makoto Hatano, Makiko Wakuta, Kazutaka Yamamoto, Eika Arai, Miho Enoki, Kazushi Fujimoto, Kazuhiko Yamauchi, Keijiro Ishikawa, Koh-Hei Sonoda, Kazuhiro Kimura   +9 more
doaj   +1 more source

Evaluating the outcomes of pluripotent stem‐cell‐derived photoreceptor transplantation in retinal repair

The FEBS Journal, EarlyView.
Transplantation of stem cell‐derived photoreceptors in retinal repair. We summarize methods for differentiating stem cells and describe surgical techniques for transplanting photoreceptor precursors to restore visual function (A). The effectiveness of these techniques is assessed with behavioral (B) and in vitro assays (C) using mouse models that mimic
Darin Zerti, Birthe Dorgau, Evelyne Sernagor, Lyle Armstrong, Majlinda Lako, Gerrit Hilgen   +5 more
wiley   +1 more source

Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial [PDF]

, 2014
Background: Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 ...
Bailey, C., Binns, A. M., Margrain, T., Mckeague, C.   +3 more
core   +2 more sources

A systematic integrative review of specialized nurses' role to establish a culture of patient safety: A modelling perspective

Journal of Advanced Nursing, EarlyView.
Abstract Aims To understand specialized nurses' role in the culture of patient safety and their ability to promote and enforce it within healthcare. Design A systematic integrative review using the approach of Whittemore and Knafl. Methods Systematic literature search for qualitative, quantitative and mixed‐methods studies, followed by data evaluation,
Manela Glarcher, Mojtaba Vaismoradi
wiley   +1 more source

Análise Retrospetiva Sobre a Utilização em Contexto Real do Ranibizumab em Doentes com Degenerescência Macular da Idade Exsudativa em Portugal [PDF]

, 2017
INTRODUCTION: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice ...
Canelas, J, Carneiro, A, Flores, R, Goncalves, C, Meireles, A, Monteiro-Grillo, M, Rosa, P, Silva, R, Teixeira, C   +8 more
core   +3 more sources